clinical trial · NCT03319940
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Small Cell Lung CarcinomaTarlatamabPembrolizumabCRS Mitigation Strategies
brief summary
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
started
Dec 26, 2017
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Nov 4, 2026
detailed description
This is an open-label, ascending, multiple doses, phase 1 study evaluating tarlatamab monotherapy, in combination with anti-PD1 therapy and with additional cytokine release syndrome (CRS) mitigation strategies. Tarlatamab will be administered as a short term intravenous (IV) infusion in participants with SCLC. Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
official title
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol